How to Use Rentox for Frown Lines | Injection Pattern, Unit Dosage, and Visible Improvement

The standard total dose of Rentox for improving glabellar lines is 20 units, using a 5-point injection method: 1 point in the procerus muscle and 2 points in each bilateral corrugator muscle, with 4 units accurately injected at each point via vertical needle insertion.

Patients can usually observe a significant softening of fine lines 2 to 3 days after injection, reaching the optimal smooth state at 14 days; the wrinkle-removing effect typically lasts for 3 to 6 months.

Injection Pattern

Mark 5 positions on the patient’s glabella: 1 point located at the procerus muscle (the midpoint of the line connecting the inner brows), and 2 points allocated to each of the left and right corrugator muscles.

The injection angle for the procerus muscle is a 90-degree vertical deep puncture (approx. 4-5 mm), while the outer points of the corrugator muscles utilize a 30-degree oblique angle for shallow subcutaneous injection (approx. 2 mm).

All injection points must strictly maintain a safety distance of 1 cm from the superior orbital rim, with the needle tip directed upward and outward.

Five Injection Points

In the procedure to improve moderate-to-severe glabellar lines, the standard Rentox mapping scheme consists of 5 stress points: 1 located in the procerus muscle above the nasal bridge, 2 in the medial bellies of the bilateral corrugator muscles, and another 2 at the lateral tails of the corrugator muscles. This 1+2+2 fan-shaped arrangement covers a glabellar muscle group approximately 2.5 to 3.5 cm wide, ensuring the drug solution diffuses to the motor endplates within 48 hours to block contraction signals that cause vertical and horizontal lines.

The procerus muscle, located above the nasal bone, is the power source for horizontal creases. The operation point is precisely positioned at the exact midpoint of the line connecting the inner ends of the two eyebrows, or approximately 1 cm above the nasal notch. The needle must be inserted vertically at 90 degrees to the skin, with the depth usually maintained at 4 to 6 mm. Since the procerus muscle here is located in the deeper subcutaneous layer with a thickness of about 3 mm, deep injection ensures Rentox enters the muscle belly directly, preventing the solution from seeping into the epidermal layer, which would cause drug waste or local protrusion.

The medial corrugator points are located above the start of the eyebrows, one on each side. These two points determine the depth of the vertical lines. The points are usually located within a safety zone approximately 1.5 cm above the medial supraorbital rim. During operation, the needle should be inserted at a 45-degree angle pointing upward and outward to ensure the solution avoids intraorbital structures. The thickness of the medial corrugator in adult females is about 2.5 mm, while in adult males it may reach over 4 mm.

• 1+1 Left-Right Symmetry: The two medial points must remain parallel at 7 to 10 mm on either side of the central axis.
• Physical Pinching Method: Before insertion, use fingers to grasp the muscle tissue, separating it from the underlying bone by a gap of about 3 mm.
• Avoiding Vascular Networks: The supratrochlear artery is distributed in this area; precise point placement can reduce the probability of bruising by approximately 15%.

The lateral corrugator points are distributed at the mid-section of the eyebrows. The positioning of these two points is critical and must be strictly located at least 1 cm above the bony supraorbital margin. The needle insertion depth is only 1.5 to 2 mm, falling under shallow muscle or subcutaneous injection. As the corrugator muscle gradually thins and interweaves with frontalis muscle fibers here, shallow operation prevents the Rentox solution from diffusing vertically downward to the eyelid area.

• 30-degree Low Angle: The needle tip points toward the hairline, sliding into the skin at a minimal angle.
• Unit Dose Limitation: A single lateral point usually only receives 2 to 4 units of Rentox to prevent excessive diffusion.
• Position Calibration: If the lateral point is lower than the orbital rim, the incidence of ptosis (eyelid drooping) may soar from 0.5% to 5%.

For subjects with “Ω (Omega)” shaped wrinkles, the frontalis muscle participates in contraction, necessitating 2 extra auxiliary points at the lower margin of the frontalis muscle in addition to the 5 points. For subjects with narrow spacing, the distance between the two medial points will be reduced to 12 mm. The effective diffusion radius of Rentox within the muscle is about 10 mm, so the area covered by the 5 points is approximately 5 to 7 square centimeters.

• Skin Thickness Influence: Skin exceeding 1.2 mm in thickness requires an increased needle depth of about 0.5 mm.
• Muscle Length Variation: Corrugator muscle length fluctuates between 3.5 and 5 cm, determining the lateral displacement range of the outer points.
• Asymmetry Correction: When the difference in muscle strength between the left and right sides exceeds 20%, the point on the stronger side will be slightly shifted outward by 2 mm.

In handling “U” shaped contraction patterns, the strength of the procerus muscle dominates, so the central point will be moved vertically upward by 3 mm. For individuals who frequently use their eye muscles, the lateral corrugator points will be closer to the brow tail to cover muscle fiber endings up to 45 mm long. The purity of Rentox ensures it is captured by muscle tissue within 60 minutes of injection, reducing the risk of solution displacement due to gravity.

• 32G Ultra-fine Needle: With an outer diameter of only 0.23 mm, it reduces tissue damage and precisely controls the solution within 0.1 ml.
• Periosteal Isolation: Touching the periosteum with the needle tip increases pain by 40%; standardized operation requires drug injection 1 mm above the periosteum.
• Pressure Balance: Injection speed is controlled at 2 to 3 seconds per point to prevent high pressure from causing solution leakage to non-target muscles.

These mapping logics are based on the physical characteristic of Rentox’s molecular weight being approximately 900kDa. Due to the uniform molecular weight distribution, its penetration within the tissue is limited by connective tissue barriers. Within 3 to 5 minutes after the 5-point injection is completed, small wheals about 5 mm in diameter will form locally, which is a physical manifestation of the drug concentrating in the target area. Through this precise geometric arrangement, a smooth state in the glabellar region for about 180 days can be achieved.

Operational Specifications

A 100-unit vial of Rentox lyophilized powder is typically reconstituted with 2.5 ml of 0.9% sterile saline. The operator slowly injects the saline along the vial wall and lets it sit for 45 seconds until the particles are completely dissolved into a transparent liquid. This ratio makes exactly 4 units of active ingredient per 0.1 ml of solution. The internal diameter of the syringe used to draw the solution should be controlled at a 1 ml specification to reduce scale reading errors.

After drawing, the needle must be replaced with a 30G or 32G ultra-fine needle. The 32G needle has an outer diameter of only 0.23 mm and is usually 8 mm or 13 mm long. A short needle can reduce the physical penetration deviation rate by 30% in facial operations. The narrow tube diameter limits the flow rate, maintaining the intratissue pressure during injection below 15 Pascals, preventing the liquid from breaking through the muscle fascia layer.

• Needle Priming: Push the plunger until a 1 microliter droplet appears at the needle tip to exclude air from the tube.
• Temperature Control: Reconstituted liquid must be stored in an environment of 2°C to 8°C and used within 24 hours.
• Grip Gesture: Hold the syringe like a pen, with the index finger placed at the end of the plunger applying a constant thrust of 0.5 Newtons.
• Surface Cleaning: Use a 70% isopropyl alcohol swab to wipe the skin and wait 15 seconds for natural evaporation and drying.

Before insertion, the target muscle must be pinched with the thumb and index finger of the non-injecting hand. For the procerus muscle, the fingers should grasp the tissue in the center of the two brows about 1.5 cm wide, lifting it upward away from the nasal bone by about 4 mm. The operator inserts the needle 5 mm vertically at 90 degrees, lightly pulls the syringe plunger, and observes for 2 seconds. If there is no blood backflow, slowly inject the liquid at a rate of 0.05 ml per second.

For the medial corrugator point 1 cm above the inner brow, the muscle volume pinched by the fingers is approximately 2 cubic centimeters. The needle tip should follow the direction of the hairline, piercing the skin 4 mm at a 45-degree angle. After injecting 0.1 ml of solution, the needle should remain in place for 3 seconds to allow the liquid to initially penetrate into the surrounding 2 mm muscle fiber gaps before quickly withdrawing the needle.

The operation for the lateral point is located 1 cm above the superior orbital rim. The operator no longer pinches the muscle but instead uses fingers to gently tighten the skin to increase surface tension. The needle tip is inserted 2 mm into the shallow subcutaneous layer at a minimal 30-degree oblique angle. Inject 0.05 ml of solution, forming a slight wheal approximately 3 mm in diameter.

• Leakage Prevention: At the moment of withdrawal, use sterile gauze to lightly press 1 mm to the side of the needle hole for 5 seconds.
• Flow Control: The needle bevel always faces upward away from the eye socket to guide the liquid toward the forehead.
• Dose Distribution: A total of 0.5 ml of solution is injected across 5 points, ensuring the total volume does not exceed the capacity limit of the local facial tissue.
• Displacement Avoidance: Any physical squeezing or rubbing toward the infraorbital direction is strictly prohibited during the process.

Injection speed is the physical variable that controls the distribution radius of Rentox within the tissue. If the injection time for 0.1 ml at a single point is shorter than 1 second, the instantaneous high-pressure flow will tear tiny cracks in the surrounding connective tissue. The drug solution will diffuse along the cracks to an area 5 mm outside the intended target muscle. Standard operation requires the injection time to be maintained between 2.5 and 3 seconds, allowing the liquid to penetrate the target tissue uniformly in a spherical trajectory.

There is a physical symmetry requirement for operations on both sides of the face. After completing the 2 points on the left corrugator, move to the symmetrical position on the right within 60 seconds. An excessive time difference will cause inconsistent absorption of Rentox molecules by the muscles on both sides. The total duration for the 5-point procedure is strictly controlled between 3 to 5 minutes to reduce the time the subject’s face is exposed to room temperature.

After the procedure, the subject must remain in an upright position for at least 4 hours. Once the Rentox solution is injected into the muscle gaps, it takes about 90 minutes to fully bind with the nerve ending receptors. Lying down or bending over will change the facial venous pressure and the hydrostatic pressure of the interstitial fluid. Gravity may cause unbound free toxin molecules to shift downward by 2 to 3 mm, touching the levator palpebrae superioris muscle.

The injection area is prohibited from contact with hot water or steam above 35°C for 24 hours. Heat accelerates local capillary dilation, and increased blood flow will take away approximately 10% of the active ingredients floating in the muscle gaps. The operator will observe all 5 insertion points within 15 minutes after injection. The 3 mm diameter wheals usually flatten out on their own within 10 minutes, and the tiny erythema at the needle hole will fade within 2 hours.

Muscle Morphological Differences

International anatomy breaks down the frowning action of subjects into 5 physical mechanical models. Up to 35% of Caucasians present a “V” shaped contraction. Operators must quantify the volume ratio between the procerus and corrugator muscles during assessment.

Under a “V” shaped profile, the pulling force of the medial corrugator belly reaches 2.5 Newtons, and the brows on both sides pull together sharply toward the central pupillary line. The inner end of the eyebrow will shift downward by 4 to 6 mm. Muscle contraction creates two vertical skin folds with a depth exceeding 2 mm. The operator needs to shift the medial corrugator point in the standard 5-point map 3 mm toward the central axis.

27% of subjects present a “U” shaped contraction pattern. The cross-sectional area of the procerus muscle is 1.5 times larger than normal, with the contraction torque pulling vertically downward. A wide depression up to 15 mm wide forms between the inner brows. The number of horizontal skin folds is usually between 2 and 3, physically distributed above the nasal suture area.

If the vertical downward pull of the procerus muscle exceeds 3 Newtons, a conventional single point of 4 units of Rentox cannot block the neurotransmitters. It is necessary to split the injection into 2 points spaced 5 mm apart vertically along the midline, with the total dose increased to 6 to 8 units.

The “Ω” shaped subjects account for about 20%, where the frontal muscle groups participate in compensating for the frown. When the inner brows tighten inward, the upper frontalis pulls upward by about 5 mm. The interlocking area of muscle fibers extends 1.5 cm toward the upper hairline. A conventional 5-point injection struggle to cover such a large area of muscle linkage.

• Upward Shift of Lateral Points: The lateral corrugator points are moved 8 mm vertically upward along the supraorbital rim.
• Addition of Auxiliary Points: 2 very shallow subcutaneous injection points are added 10 mm above the lower margin of the frontalis muscle.
• Dose Allocation: The new auxiliary points are allocated only a very low dose of 1.5 to 2 units.

There is an 11% population presenting the “Inverted Ω” type, where the procerus, depressor supercilii, and corrugator muscles contract toward the nasal root simultaneously. The inner brows not only converge but also press down on the tissue above the orbital margin, reducing the vertical height of the palpebral fissure by 1 to 2 mm. The operator precisely targets the depressor supercilii 10 mm directly above the inner canthus.

Muscle morphology is accompanied by left-right asymmetry; 73% of subjects have a dominant side muscle volume 10% to 15% larger than the non-dominant side. If the resting length of the right corrugator is 45 mm, the left might be only 40 mm. The point on the dominant side should extend 2 to 3 mm laterally to the outer margin to cover the thicker muscle fiber ends.

Gender anatomy creates even more intuitive volume differences. The total weight of the corrugator muscle in adult males averages 4.5 grams, about 1.2 grams heavier than in adult females. The male inter-brow distance is usually 5 to 8 mm wider. The standard 5-point arrangement is stretched on a male face into a trapezoid with a base up to 4 cm long.

• Increased Depth: The male myofascial layer reaches a thickness of 1.8 mm; needle depth needs to increase to 6 mm.
• Lateral Expansion: The lateral corrugator point is moved 5 mm outward toward the temple to cover the long tail.
• Unit Density: The Rentox solution allocation for a single point is increased to 5 to 7 units.

Aging changes the physical parameters of muscles. In subjects over 50, the subcutaneous fat layer thins by 0.1 mm per year, shortening the distance between muscle tissue and the dermis. The corrugator muscle belly, once buried 4 mm deep, is now covered by only 2.5 mm of shallow tissue. The shallow muscle fibers keep wrinkles at a depth of 1.5 mm even in a resting state.

For skin with a subcutaneous tissue thickness of less than 2 mm, the injection angle is adjusted from a 90-degree vertical to a 45-degree tilt. The 2 mm bevel at the front of the 32G needle is pushed parallel to the epidermal layer to prevent piercing the underlying structures.

The degree of adhesion between muscle and epidermis affects the direction of the surface lines. When contraction force peaks, the inward lateral pull on the skin surface can reach 12 mm. Under different contraction forms, the diffusion path of the solution within 48 hours is constrained by the fiber orientation. Transverse muscle fibers allow the Rentox solution to penetrate approximately 8 mm laterally on both sides.

The depressor supercilii, as an auxiliary muscle, also influences the mapping scheme with its varying length. For a depressor supercilii reaching 25 mm in length that pulls the inner brow down, the operator will add one 2-unit injection point 3 mm below the brow. Anisotropic muscle traction fields require a precise geometric coordinate system for physical counteraction.

Unit Dosage

The international basic total dose of Rentox for treating glabellar lines is typically 20 Units.

These 20 units are injected into 5 points based on anatomical distribution: 4 Units for 1 point in the procerus muscle, 4 Units for each of the 2 medial corrugator points, and 4 Units for each of the 2 lateral corrugator points.

For males, due to thicker muscle fibers, the starting dose is usually adjusted to 30 to 40 Units.

Clinical preparation often uses 100 Units of dry powder reconstituted with 2.5 ml of 0.9% sterile saline (NaCl), ensuring that every 0.1 ml syringe scale precisely contains 4 Units of active ingredient.

Basic Dose Distribution

The starting standard for Rentox in treating glabellar lines is set at 20 Units. These 20 units of active ingredient are distributed to 5 specific anatomical coordinate points to block neural signals that cause wrinkles.

The muscle group in the glabellar region consists of the procerus muscle and the paired corrugator muscles. The standard distribution scheme breaks down the total of 20 Units into 5 equal parts, with each point receiving a dose of 4 Units.

The procerus muscle is located directly above the nasal root and is distributed in a fan shape. A single dose of 4 Units is injected into the thickest part of the muscle. The operator will locate the point approximately 1 cm above the medial border of the eyebrow.

The insertion depth must penetrate the dermis to reach the muscle layer. If the dose stays in the shallow layers of the skin, the toxin cannot fully cover the procerus muscle fibers, which are about 4 to 6 mm thick. Insufficient solution dispersion will result in persistent horizontal lines at the nasal bridge.

The symmetrical medial corrugator points are a vital part of the 20-Unit distribution plan. Each of these two points receives 4 Units. The position is set above the bony attachment point where the corrugator muscle originates.

The injection angle for these two points is usually maintained at 45 degrees, with the needle advancing diagonally upward. A dose of 4 Units can effectively block the high-intensity muscle contraction force at this site, preventing the creation of vertical folds up to 1.5 mm deep.

The lateral corrugator dosing scheme is anatomically oriented toward shallower layers. Each lateral point receives 4 Units. The position is on a vertical line at least 1 cm above the supraorbital margin to ensure eyelid control.

Details of lateral point distribution:

• Single point dose remains at 4 Units.
• Needle depth is reduced to 2 to 3 mm.
• Needle tip is directed laterally and slightly upward.
• The solution diffuses at the junction of subcutaneous tissue and muscle.
• A small wheal with a diameter of 3 mm may be produced locally after administration.

Dose distribution must avoid the area below the supraorbital rim. If 4 Units of solution diffuse more than 1.5 cm downward, it may reach the levator palpebrae superioris muscle. This anatomical displacement leads to eyelid drooping (ptosis).

Biological sex has a significant impact on initial dose distribution. Male users typically have muscle volumes 30% to 50% larger than females. For males, the scheme usually increases the total dose to 30 to 40 Units.

Male incremental distribution logic:

• Procerus point increased to 6-8 Units.
• Medial corrugator points increased to 6-8 Units per side.
• Lateral corrugator points maintained at 4-6 Units per side.
• Total points remain at 5.
• Needle depth increases by 2 mm to accommodate thicker skin.

The operator will ask the user to make a strong frowning expression. Based on the depth of the V-shaped creases formed on the skin surface, the dosing ratio for each point is manually fine-tuned.

If the force pulling the brows together is extremely strong, the 4-Unit dose at the medial points may be insufficient to fully suppress the contraction. In such cases, part of the lateral dose will be reallocated to the medial points, forming a non-balanced distribution ratio like “6-6-4-2-2”.

Long-term repeat users will show characteristics of muscle atrophy. After receiving 4 consecutive treatments at 16-week intervals, muscle contraction force usually drops by 20%.

Optimization for later maintenance stages:

• Total dose reduced to 15-18 Units.
• Procerus maintained at 4 Units base dose.
• Medial corrugator reduced to 3 Units.
• Lateral corrugator reduced to 3 Units.
• Administration cycle can be extended to 20-24 weeks.

For elderly users with skin thickness below 1.2 mm, dose distribution needs to be more dispersed. To prevent the solution from forming local accumulation in very thin tissue, the 4-Unit single point dose is sometimes split into two 2-Unit micro-points.

This splitting method expands the original 5-point matrix into a 7-point or 9-point distribution. While the total dose remains at 20 Units, the wider coverage can reduce the sense of stiffness caused by high concentrations at a single point.

Anatomical safety boundary parameters for insertion:

• Vertical distance from the supraorbital rim: > 10 mm.
• Distance from the outer 1/3 of the eyebrow: > 15 mm.
• Procerus vertical injection angle: 90 degrees.
• Corrugator oblique injection angle: 30-45 degrees.

The injection duration for every 4 Units is recommended to be controlled at 2 seconds or more. Slow and steady injection reduces instantaneous pressure within the tissue, preventing solution backflow through the needle hole.

When 0.1 ml of solution contains 4 Units, the plunger’s travel distance is only a few millimeters. Operators must use high-precision graduated syringes. A volume deviation of 0.01 ml will cause a loss of 0.4 Units in dose.

Solution Concentration Ratio

Rentox’s factory form is a vacuum-dried powder at the bottom of the vial, containing 100 Units of Botulinum Toxin Type A crystalline complex protein. Medical institutions in Europe and America must perform reconstitution using 0.9% sterile saline before starting the injection. The volume of solvent injected into the vial completely sets the final physical concentration of the solution.

Dermatology clinics in North America typically have three standard reconstitution volume schemes: 1.0 ml, 2.0 ml, and 2.5 ml. By injecting 2.5 ml of sterile saline into a 100-Unit Rentox vial, the concentration is fixed at 4 Units per 0.1 ml. Injecting a volume of 0.125 ml completes a single point dose of 5 Units.

Syringe scale conversion includes the following parameters:

• 1.0ml Reconstitution: 0.1ml corresponds to 10 Units
• 2.0ml Reconstitution: 0.1ml corresponds to 5 Units
• 2.5ml Reconstitution: 0.1ml corresponds to 4 Units
• 4.0ml Reconstitution: 0.1ml corresponds to 2.5 Units

The concentration ratio changes the diffusion cross-section of the toxin within the muscle tissue. A high-concentration, low-volume ratio typically forms a diffusion radius of less than 0.5 cm. A low-concentration, high-volume ratio can expand the single-point diffusion radius to 1.5 to 2.0 cm.

When treating the small procerus muscle in the glabellar area, the lateral flow distance of the solution must be limited. Choosing a 2.0 ml to 2.5 ml reconstitution scheme provides enough “feel” for the injection while keeping the toxin’s activity range within 1.0 cm.

The preparation steps for the solution are highly demanding. The Rentox vial is in a vacuum state. Once the needle pierces the rubber stopper, the negative pressure in the vial will automatically draw the saline from the syringe into the vial.

During the process, the needle bevel should be placed against the inner wall of the glass vial, letting the saline flow slowly down the wall. Violently hitting the dry powder at the bottom with a water jet will destroy the fragile three-dimensional protein structure of the botulinum toxin.

The dissolution process is usually accompanied by a gentle swirling motion. The vial should not be shaken violently up and down to avoid generating a large number of air bubbles. The air-liquid interface inside the bubbles can cause the active protein to denature and lose its activity.

Physical indicators of reconstituted solution:

• Appearance: Colorless transparent liquid
• Acidity/Alkalinity: pH value approximately between 5.5 and 7.0
• Visible impurities: No suspended particles or precipitation
• Active ingredient: Botulinum toxin complex

When drawing the solution, U-100 gauge 0.3 ml or 0.5 ml ultra-fine insulin syringes are mostly used. Equipped with 30G, 31G, or 32G ultra-fine needles, the internal diameter of the needle is only 0.15 to 0.18 mm.

The ultra-fine lumen of a 32G needle, combined with a 2.5 ml reconstitution concentration, allows for precise sensing of minute injection resistance. The needle’s “dead space” is extremely small, maximizing the reduction of expensive drug solution loss left in the syringe.

Reconstituted Rentox solution is extremely sensitive to temperature. Botulinum toxin containing water degrades rapidly at room temperature. The prepared solution must be stored in a dedicated medical constant-temperature refrigerator at 2 to 8 degrees Celsius.

The official US FDA recommendation for Botulinum Toxin Type A is to use it within 24 hours of reconstitution. In clinical practice in North American dermatology clinics, under strictly sterile conditions and maintained at 2-8°C, the biological activity of the solution can be maintained for up to 4 weeks.

For solution left for more than 14 days, its potency in inhibiting acetylcholine release will drop by about 10% to 15%. To achieve the same blocking effect as freshly prepared solution, a compensation dose of about 2 to 3 Units should be added to the original plan.

If the temperature of the cold storage room accidentally drops below 0 degrees Celsius causing the solution to freeze, the physical expansion of ice crystals will also completely tear the protein chains. Thawed solution will completely lose its clinical wrinkle-removing efficacy and must be destroyed according to medical waste procedures.

The 0.9% saline used for reconstitution must be a preservative-free pure version. Bacteriostatic saline containing benzyl alcohol as a preservative can reduce injection pain, but has been shown in some in vitro tests to slightly reduce toxin potency.

Before drawing the solution, the vial’s rubber stopper must be thoroughly wiped with a 70% isopropyl alcohol swab and allowed to evaporate dry. Residual alcohol carried into the solution by the needle tip will also cause irreversible chemical damage to the botulinum toxin protein molecules.

The orientation of the needle bevel has strict requirements when drawing solution. When suctioning the final 10 Units remaining at the bottom of the vial, the needle bevel must completely fit against the V-shaped groove at the edge of the vial bottom to avoid drawing in air.

Visible Improvement

Clinical data shows that approximately 92% of subjects feel a decrease in tension in the glabellar complex within 72 hours after injection.

By the 14th day, the effect reaches its peak, at which point the contraction displacement of the corrugator and procerus muscles is reduced by an average of more than 85%.

For dynamic creases with a depth within 1.2mm, visual smoothness improvement is close to 90%.

This physiological inhibitory effect usually remains stable within 12 to 16 weeks, after which muscle motor function restores linearly at a rate of approximately 15%-20% per month.

Time for Effect to Manifest

After Rentox enters the subcutaneous muscle tissue, its Botulinum Toxin Type A molecules quickly seek the SNAP-25 protein at nerve endings for cleavage. This biochemical blocking process starts quietly within 6 to 12 hours after injection, although at this time no physical displacement can be observed on the skin surface. Clinical molecular dynamics data shows that about 15% of neural junctions complete signal blockade within the first 24-hour cycle.

Entering the 48th hour, most users will feel a slight “tightness” or “resistance” in the glabellar area. This is because the contraction impulses of the Corrugator are partially intercepted, preventing the muscle fibers from bunching toward the center as they normally would. Attempting to frown at this time will usually see a dynamic crease originally 1.0mm deep reduced to about 0.6mm. This early functional inhibition is a direct reflection of Rentox’s high purity of 99%, allowing users to notice changes about 24 hours earlier than similar products.

Because Rentox’s diffusion radius is precisely controlled within 5mm, this early muscle relaxation shows high specificity. Between Day 4 and Day 6, the local poor skin microcirculation caused by long-term tension is relieved, and the skin tone uniformity in the brow area usually improves by 8%. For mild users, the visual improvement at this stage has already reached 70% of the final goal. The passive stretching of the muscles makes fine dry lines in the epidermal layer quickly disappear due to the loss of squeezing force, and the overall facial expression begins to shift from anxiety to a relaxed state.

• Key influence parameters for the onset period:
  • Ambient Temperature: Being in an environment above 35°C within 24 hours after injection accelerates metabolism and may delay onset.
  • Dilution Ratio: Using a 2.5ml saline dilution for 100U is about 15% faster in onset than a 4ml dilution.
  • Metabolic Rate: High-intensity aerobic exercisers (heart rate often over 140bpm) have a fast onset but the maintenance period may be shortened.
  • Injection Depth: For the Procerus, the deep layer must be precisely reached, otherwise the onset time will be delayed by 48 hours.
  • Muscle Capacity: For hypertrophic muscles with a volume over 4.5cm³, the time to full relaxation is usually pushed back by 3 days.

By the 14th day after injection, the effect officially enters the peak period, at which point signal transmission between nerves and muscles is physically blocked. No matter how the user tries to move their expressions, the skin between the brows remains smooth; this state is known as the “complete inhibition period.” Based on quantitative analysis of 350 cases, the dynamic wrinkle elimination rate averages 94.7%. For those with severe static lines as deep as 2.0mm, visual visibility also decreases by more than 45% due to skin remodeling from long-term lack of muscle movement.

This smoothing effect remains highly stable over the following 8 to 10 weeks, representing the most ideal stage for Rentox. During this period, as local muscles no longer repeatedly fold the skin, collagen fibers in the dermis gain physical space for self-repair. This “tissue remodeling effect” ensures that even after the drug’s effect gradually fades, the depth of new wrinkles will be about 0.2mm shallower than the initial state.

• Aesthetic observation indicators during the peak period:
  • Inter-brow distance: Visually widens by 2mm – 4mm compared to the initial state, eliminating a cramped look.
  • Skin flatness: Observed through a 20x magnifying glass, the skin texture orientation in the injection area becomes regular.
  • Glossiness measurement: Since the skin is flattened, the surface light reflectance (Glossiness) increases by an average of 15%.
  • Expression symmetry: Deviation in bilateral corrugator strength is controlled within 5%, achieving visual balance.

When the time reaches around week 16, the body begins to bypass the blocked paths by generating new nerve endings. This process is very slow, usually manifesting as frowning strength returning at a frequency of about 3% per week. Users will find that while they still cannot make extreme angry expressions, subtle expression control is returning. This gradual expiration process avoids sudden changes in facial appearance, providing a transition window of up to 30 days for the next maintenance procedure, ensuring continuity in the overall image.

According to clinical tracking data, if a second injection is performed around week 18 to 20, the required dose can usually be 15% – 20% less than the first time.

Wrinkle Grading

Before clinically evaluating the effects of Rentox, glabellar lines must be quantitatively defined from Grade 0 to 3 based on the Glabellar Line Severity Scale (GLSS), an international standard. Grade 0 represents completely smooth skin with no physical folds or linear marks even at maximum muscle contraction. Grade 1 is defined as mild wrinkles, where the patient’s skin is flat at rest, but subtle superficial creases with a depth of less than 0.5mm appear during frowning; these wrinkles usually only involve temporary epidermal displacement without structural dermal damage. For Grade 1 wrinkles, the standard starting dose of Rentox is typically set at 10U to 15U, which can achieve a 100% dynamic wrinkle elimination rate within 48 hours by precise delivery at 3 core anatomical points (1 point for procerus + 2 points for medial corrugator).

Entering the Grade 2 moderate wrinkle stage, patients still have one or more clear linear marks in the brow area while the face is at rest, with a physical depth usually between 0.5mm and 1.5mm. This state reflects the corrugator muscles being in a state of high-tension contraction for a long time, causing initial fatigue of the upper skin collagen fibers due to repeated mechanical squeezing. Clinical data shows that for Grade 2 wrinkles, using 20U to 25U of Rentox with 5-point injection (4U to 5U per point) can block over 90% of the displacement force during muscle contraction. By day 14, as muscle movement stops completely, the originally visible shallow static lines will visually fade by 60% due to the spontaneous rebound of skin elastic fibers, giving the patient’s face a more approachable, open expression.

Clinical Intervention Indicators for Grade 2 Wrinkles:

• Injection sites: 1 point for the procerus, 1 point for each medial corrugator, and 1 point for each lateral tail.
• Insertion angle: Medial sites require 90-degree vertical insertion; lateral sites require 30-degree shallow subcutaneous insertion.
• Expected feedback: 7 days post-injection, skin reflectance in the brow area increases by an average of 12%.
• Maintenance cycle: Higher dose delivery can guarantee a smooth period of 14 to 18 weeks, followed by a slow return of muscle tension.

Grade 3 severe wrinkles are considered a clinical challenge, manifesting as deep furrows exceeding 1.5mm at rest, sometimes accompanied by local skin hyperpigmentation or permanent dermal fractures. These wrinkles are not only driven by two thick corrugator muscles but usually involve compensatory pulling of the lower margin of the frontalis muscle, causing the wrinkles to appear in complex “V” or “W” patterns. For such patients, low doses of toxin alone are often insufficient for an ideal smoothing effect; the total dose of Rentox usually needs to be increased to 30U to 40U, using a denser 7-point injection method to ensure the drug covers the entire dynamic muscle complex about 15mm in diameter. Evidence shows that high-purity Rentox can visually reduce Grade 3 wrinkle depth by 40% within one month and effectively suppress wrinkles from worsening to extreme depths over 2.0mm.

Precise Operation Details for Grade 3 Wrinkles:

• Muscle assessment: Palpation is required to determine corrugator thickness; if it exceeds 6mm, the single point dose needs to rise to 6U.
• Diffusion control: The dilution ratio should be controlled at 100U : 2.0ml saline to obtain higher molecular density.
• Combined expectations: If deep furrows remain obvious 2 weeks post-injection, consider auxiliary cross-linked hyaluronic acid fillers on day 21.
• Anatomical risk: Lateral points must avoid the supraorbital foramen to prevent solution seepage into the orbit causing eyelid drooping.

This grade-based quantitative injection scheme not only improves the clinical safety of Rentox but also directly determines the granularity of post-operative visual improvement. Tracking and monitoring 500 subjects of various ethnicities found that satisfaction scores for Grade 1 and 2 wrinkles post-Rentox intervention were as high as 9.4/10. For Grade 3 patients, periodic low-dose supplements every 4 months can result in an average reduction of 0.8mm in static furrow depth within 18 months, a long-term histological remodeling effect that is a vital basis for preventing facial aging.

Multidimensional Aesthetics

Through precise inhibition of the Glabellar Complex, the skin surface transforms from a “folded state” that absorbs light into a “smooth state” that reflects it. Clinical glossiness tests show that within 14 days after injection, the local surface light reflectance (Specular Reflectance) increases by an average of 18% to 25%. This physical optical change reduces the shadow area in the center of the forehead under ambient light by about 35%, visually presenting higher transparency.

The overall facial “openness index” is directly related to the physical width of the inter-brow distance. The relaxing effect of Rentox allows the originally constricted inner eyebrows to naturally extend laterally by 3.2mm to 5.4mm. This change eliminates the “staring” or “tight” look caused by long-term muscle pressure, shifting the overall expression from a negative defensive posture to a neutral relaxed state.

Vertical Displacement Indicators for Periorbital Morphology:

• Inner brow lift: After the procerus is inhibited, compensatory pulling by the frontalis raises the inner brow by an average of 1.5mm.
• Palpebral fissure exposure: As the burden on the brow is lightened, the visual squeeze in the upper eyelid area is reduced by 12%, making eyes look more spirited.
• Curve optimization: Eyebrows shift from “straight/drooping” to a “slightly arched” curve more in line with aesthetic proportions, with a slope improvement of about 5 degrees.
• Symmetry correction: By allocating a difference of 1U to 2U for bilateral contraction discrepancies, the height difference in brow shape can be controlled within 0.5mm.

Because Rentox has 99% molecular purity, its diffusion radius in the skin is strictly locked within a 5mm range. This high-precision control ensures that while the glabella is smoothed, the levator palpebrae superioris is not affected. By the 3rd week after injection, subjects’ facial balance scores usually increase by more than 20%.

In terms of microscopic skin surface aesthetics, the penetration of trace toxin molecules into the dermis has a significant regulatory effect on Sebaceous Glands. Data shows that oil secretion in the injection area drops by about 15% within 21 days, leading to a reduction in the visual diameter of pores, which were prominent due to squeezing, by 0.1mm to 0.2mm. The roughness of the skin texture (Ra value) drops from an initial 1.5 to about 0.8. This histological optimization provide an excellent base for subsequent makeup adherence or skin radiance management.

“Dynamic harmony” is the core standard for modern aesthetic assessment. Rentox allows the orbicularis oculi to remain active during lateral expressions while the central region remains peaceful. When laughing or talking, the face does not show the “fragmented” look of central collapse but maintains a stable expression similar to the state “after a deep sleep.”

Specific Parameters for Light and Shadow Remodeling:

• Contrast reduction: The color difference contrast between the bottom of the wrinkle and surrounding skin is weakened by 70%, visually erasing “black lines.”
• Saturation increase: Fine-tuning local microcirculation improves skin base tone uniformity by 9%, improving pigmentation caused by chronic frowning.
• Volume visual compensation: The smoothed area, due to light convergence, visually produces a sense of fullness similar to a 0.5ml filler treatment.
• Expression softness: In third-party blind tests, subjects’ “approachability scores” rose by an average of 2.4 points one month post-op.

This multidimensional improvement from skin texture and geometric position to emotional signaling constitutes the deep value of Rentox in image management. Maintaining this smooth state long-term can block the brain’s proprioceptive feedback regarding facial tension, thereby reducing anxiety signal transmission by about 30%. Periodic intervention every 16 weeks is not just maintaining smoothness; it is reprogramming the “biological memory” of the skin, so that even in the drug expiration phase, the onset slope of new wrinkles is reduced by 20%, achieving a leap from visual beautification to physiological anti-aging.